424 related articles for article (PubMed ID: 32871345)
41. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
42. Protein degradation: a validated therapeutic strategy with exciting prospects.
Lebraud H; Heightman TD
Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
[TBL] [Abstract][Full Text] [Related]
43. Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.
Goracci L; Desantis J; Valeri A; Castellani B; Eleuteri M; Cruciani G
J Med Chem; 2020 Oct; 63(20):11615-11638. PubMed ID: 33026811
[TBL] [Abstract][Full Text] [Related]
44. Targeted protein degradation: A promise for undruggable proteins.
Samarasinghe KTG; Crews CM
Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
[TBL] [Abstract][Full Text] [Related]
45. Degraders in epigenetic therapy: PROTACs and beyond.
Dai XJ; Ji SK; Fu MJ; Liu GZ; Liu HM; Wang SP; Shen L; Wang N; Herdewijn P; Zheng YC; Wang SQ; Chen XB
Theranostics; 2024; 14(4):1464-1499. PubMed ID: 38389844
[TBL] [Abstract][Full Text] [Related]
46. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
47. [Application of PROTACs in Hematological Malignancies--Review].
Jia YN; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
[TBL] [Abstract][Full Text] [Related]
48. Proteolysis-targeting chimeras for targeting protein for degradation.
Qi J; Zhang G
Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
[TBL] [Abstract][Full Text] [Related]
49. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
[TBL] [Abstract][Full Text] [Related]
50. Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs.
Gong L; Cui D; Xiong X; Zhao Y
Adv Exp Med Biol; 2020; 1217():317-347. PubMed ID: 31898236
[TBL] [Abstract][Full Text] [Related]
51. Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy.
Song Y; Dong QQ; Ni YK; Xu XL; Chen CX; Chen W
Int J Nanomedicine; 2024; 19():5739-5761. PubMed ID: 38882545
[TBL] [Abstract][Full Text] [Related]
52. Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors.
Hua L; Zhang Q; Zhu X; Wang R; You Q; Wang L
J Med Chem; 2022 Jun; 65(12):8091-8112. PubMed ID: 35686733
[TBL] [Abstract][Full Text] [Related]
53. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
[TBL] [Abstract][Full Text] [Related]
54. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
55. mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation.
Xue X; Zhang C; Li X; Wang J; Zhang H; Feng Y; Xu N; Li H; Tan C; Jiang Y; Tan Y
MedComm (2020); 2024 Feb; 5(2):e478. PubMed ID: 38374873
[TBL] [Abstract][Full Text] [Related]
56. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.
Chernobrovkin AL; Cázares-Körner C; Friman T; Caballero IM; Amadio D; Martinez Molina D
SLAS Discov; 2021 Apr; 26(4):534-546. PubMed ID: 33445986
[TBL] [Abstract][Full Text] [Related]
57. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
58. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
Zhang R; Xie S; Ran J; Li T
J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
[TBL] [Abstract][Full Text] [Related]
59. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
60. Progress on small-molecule proteolysis-targeting chimeras.
Huang W; Wang B; Zhang Z; Zhang C; Zeng S; Shen Z
Future Med Chem; 2019 Oct; 11(20):2715-2734. PubMed ID: 31571504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
